On-Track to Investor Day Commitments
Management reiterated they are on track to meet Investor Day commitments, targeting a sustainable Medicare Advantage margin of at least 3% in 2028 and making progress in 2027.
April 29th, 2026
Summary
- Earnings Call Date:
- 2026-04-29
- Change Since:
- +48.75%
- Next Earnings Date:
- 2026-07-29
Earnings Call Sentiment
PositiveThe call conveyed constructive progress on strategic priorities — membership growth, CenterWell expansion, balance sheet improvements, operational transformation, and measured Stars progress — while candidly acknowledging persistent headwinds: medical cost trend outpacing funding, elevated early-year reserves, potential put-option cash exposure, and the need to consider benefit adjustments in 2027. Management emphasized prudence in reserving, disciplined bidding, and multiple levers (operational improvements, M&A, pricing) to meet the 2028 margin objective.
Company Guidance
Humana reiterated that it is “where we expect to be” and is focused on returning to a sustainable individual MA margin of at least 3% by 2028 (with progress in 2027), expects to double individual MA margin in 2026 (adjusted for Stars), and will remain disciplined in pricing and benefit design; operational and capital moves cited include Medicaid growth of ~50,000 lives, CenterWell primary care adding ~110,000 patients (22.5% sequential growth) and the Max Health acquisition, early HEDIS closure ~5% ahead year-over-year on a per‑member basis, IBNR up ~35% sequentially vs ~22% Medicare membership growth, a Q2 MLR guide slightly above ~91%, completion of $1.0B junior subordinated notes in March to fund 2027 maturities, mitigation of >$3.0B in 2026 capital contribution requirements, and a potential Welsh Carson put exposure of roughly $1.0–$1.5B (planned for in the funding plan), while maintaining dividends, limiting buybacks to offset dilution and expecting CenterWell seasonality/operating metrics to normalize through the year.
Doubling Individual MA Margin in 2026 (Adjusted for Stars)
Company expects to double individual Medicare Advantage margin in 2026 (adjusted for Stars), demonstrating meaningful margin improvement versus prior periods (management reiterated this as a core target).
Membership and Medicaid Growth
Medicaid membership grew by approximately 50,000 lives driven by January program starts in Michigan, Illinois and South Carolina; overall Medicare Advantage membership trajectory described as 'on track' by management.
CenterWell Growth and Strategic M&A
CenterWell reported strong growth across businesses: primary care patients grew ~110,000 sequentially (22.5% sequential growth). Humana completed acquisition of Max Health to expand CenterWell reach; CenterWell also expanding agnostic pharmacy and home businesses.
Stars & Quality Momentum
Company remains confident on returning to top-quartile Stars by BY'28; early BY'29 efforts are translating to improved activation and outcomes — Q1 GAAP HEDIS closure pace on certain metrics is ~5% ahead of last year on a per-member basis.
Balance Sheet and Liquidity Enhancements
Executed $1.0 billion junior subordinated notes in March; used subsidiary reinsurance and legal entity changes to mitigate over $3.0 billion in 2026 capital contribution requirements; maintaining dividend levels and limiting buybacks to offset dilution while pursuing noncore divestitures.
Prudent Reserving and Improved Claims Monitoring
IBNR and claims monitoring practices were managed prudently early in the year; management enhanced anomaly detection and first-time payment accuracy to detect and react to trends faster, improving visibility into cost trends and payment integrity.
Operational Efficiency Initiatives
Progress on operating model changes including centralization, increased outsourcing and automation; a transformation office has been stood up to track initiatives, provide surge resources, and accelerate execution of cost and process improvements.
Operator
Good day, and thank you for standing by. Welcome to Humana's First Quarter Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I'd now like to hand the conference over to Lisa Stoner, Vice President of Investor Relations. Please go ahead.
Lisa Stoner
Thank you, and good morning. I hope everyone had a chance to review our press release and prepared remarks, which are available on our website. We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer; and Chief Financial Officer, Celeste Mellet. Following these remarks, we will host a question-and-answer session where Jim and Celeste will be joined by George Renaudin, Humana's President of Insurance segment; and Dr. Sanjay Shetty, President of Center well. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially.
Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our fourth quarter 2025 earnings press release as they relate to forward-looking statements, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. Today's press release, our historical financial news release and our fil...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free